• Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.
DISCUSSION
Heparins are present as cell surface glycosaminoglycans and have crucial regulatory roles in normal physiological processes and pathophysiological conditions, including tumor onset, proliferation, and metastasis [1] [2] [3] [4] . Possible antitumor effects of heparin include prevention of metastasis via inhibition of heparanase and interaction with P-selectin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Heparin administration is limited by its anticoagulant effects. Necuparanib is a noncytotoxic, glycol-split, heparan sulfate mimetic intended to treat advanced malignancies. Necuparanib is rationally engineered from heparin through a process that reduces anticoagulant activity while preserving activity against a number Clinical Trial Results of heparin-binding proteins involved in tumor progression and metastasis. [15] [16] [17] This is the first clinical evaluation of necuparanib, a novel therapeutic agent, which was conducted in patients with metastatic pancreatic adenocarcinoma. Necuparanib in combination with nab-paclitaxel and gemcitabine demonstrated acceptable tolerability. No clear dose-proportional trends in individual adverse events (AEs) were observed. The most common AEs had comparable rates, when necuparanib was administered with gemcitabine with or without nabpaclitaxel, to what would be expected with chemotherapy alone. The grade 3/4 hematological toxicities observed in this study in the necuparanib 1 nab-paclitaxel and gemcitabine cohort were similar to those observed in the Von Hoff phase III MPACT trial (neutropenia, 3% vs. 38%; anemia, 3% vs. 13%; and thrombocytopenia, 0% vs. 13%, respectively). No grade 3/4 AEs of leukocytosis, febrile neutropenia, epistaxis, pulmonary embolism, deep vein thrombosis, phlebitis, or hematuria were reported with the necuparanib 1 nab-paclitaxel and gemcitabine regimen.
Based on collective safety and on PK, progressive disease (PD), biomarker, and efficacy data, a 5 mg/kg necuparanib dose, with capping at 450 mg, providing for a reasonable injection volume (i.e., two injections daily), was selected for further clinical evaluation in part B (randomized phase II trial). Pharmacodynamic data (i.e., hepatocyte growth factor) showed saturation with necuparanib 5 mg/kg and subtherapeutic levels of anticoagulation, which may be beneficial for thrombosis prevention. Promising antitumor activity was observed, as evidenced by survival and response data, with an overall disease-control rate of 63% when all dose cohorts were pooled. Similarly, promising effects on reduction in Carbohydrate antigen 19-9 (CA19.9) levels from baseline with necuparanib treatment were observed. The median overall survival for patients who received at least one dose (13.1 months) and at least one cycle (15.6 months) of necuparanib 1 nab-paclitaxel 1 gemcitabine compared favorably with the phase III data for nab-paclitaxel 1 gemcitabine (8.5 months), differences in sample sizes and study populations notwithstanding [18] .
These encouraging phase I results supported further clinical investigation in part B of this two-part study; however, the phase II portion of the trial was discontinued following a planned interim futility analysis, which did not show a sufficient level of efficacy to warrant continuation of study accrual. The phase II results will be reported separately. Type of Study -2 3 1 3
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This was a phase I, open-label, multiple ascending-dose study of necuparanib given as monotherapy and then in combination with nab-paclitaxel and gemcitabine for patients with newly diagnosed untreated metastatic pancreas adenocarcinoma. Following completion of the first two cohorts (0.5 and 1.0 mg/kg necuparanib 1 gemcitabine), a protocol amendment in 2013 added nab-paclitaxel to the regimen following the presentation of MPACT study results supporting the combination. Dose escalation was conducted via a modified 3 1 3 design and occurred if all patients in the studied cohort completed cycle 1 without a dose-limiting toxicity (DLT). If a DLT was observed in one patient in the initial cohort of three to four patients, the cohort was expanded to six or seven patients. Dose escalation continued until the maximum tolerated dose (MTD) was defined. The protocol was modified during cohort 6 dosing to specify a maximum necuparanib dose of 450 mg (maximum of two injections of 225 mg/1.5 mL for each injection) following indications that daily doses greater than this were associated with elevated coagulation parameters. Dose escalation was to be terminated if two patients in the same cohort experienced a DLT in cycle 1. A DLT was defined as any AE judged by the investigator to be drug-related and assessed as grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Safety data in patients who received at least one dose of at least one of the study drugs were summarized by treatment group, and descriptive statistics were calculated for quantitative data and differences from baseline, as appropriate. Pharmacokinetic and PD parameters were calculated using noncompartmental methods and summarized by treatment group using descriptive statistics. AEs grade 3 or higher, probably/definitely related to necuparanib (patients receiving >1 necuparanib 1 nab-paclitaxel 1 gemcitabine)
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n (%) patients are shown. Adverse events have been sorted by necuparanib 1 gemcitabine 1 nab-paclitaxel (cohort 3-7 total) results. Abbreviations: -, no adverse event; ", increased; AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co, cohort.
O'Reilly, Roach, Miller et al. AEs of leukocytosis, febrile neutropenia, epistaxis, pulmonary embolism, deep vein thrombosis, phlebitis, or hematuria were reported with the necuparanib 1 nab-paclitaxel and gemcitabine regimen. Based on collective safety and on pharmacokinetic, progressive disease, biomarker, and efficacy data, a 5 mg/kg necuparanib dose, with capping at 450 mg, providing for a reasonable injection volume (i.e., two injections daily), was selected for further clinical evaluation in part B. Progressive disease data (i.e., hepatocyte growth factor) showed saturation with necuparanib 5 mg/kg and subtherapeutic levels of anticoagulation, which may be beneficial for thrombosis prevention. Promising antitumor activity was observed, as evidenced by survival and response data, with an overall disease-control rate of 63% when all dose cohorts were pooled. Similarly, promising effects on reduction in CA19.9 levels from baseline with necuparanib treatment were observed. The median OS for patients who received at least one dose (13.1 months) and at least one cycle (15.6 months) of necuparanib 1 nab-paclitaxel 1 gemcitabine compared favorably with the phase III data for nab-paclitaxel 1 gemcitabine (8.5 months), differences in sample sizes and study populations notwithstanding.
These encouraging phase I results supported further clinical investigation in part B of this two-part study; however, the phase II portion of the trial was discontinued following a planned interim futility analysis, which did not show a sufficient level of efficacy to warrant continuation of study accrual. The phase II results will be documented in a separate publication. Figure 1 . Dose escalation and disposition in patients receiving at least one dose of necuparanib.
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Abbreviations: aPTT, activated partial thromboplastin time; DLT, dose-limiting toxicity; Gem, gemcitabine; HGF, hepatocyte growth factor; LFTs, liver function tests; NabP, nab-paclitaxel; Necu, necuparanib; PK, pharmacokinetics. Abbreviations: Gem, gemcitabine; NabP, nab-paclitaxel; NE, not evaluable; Necu, necuparanib; PD, progressive disease; PR, partial response; SD, stable disease. n (%) patients are shown. Adverse events have been sorted by necuparanib 1 gemcitabine 1 nab-paclitaxel (cohort 3-7 total) results. Abbreviations: -, no adverse event; ", increased; AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co, cohort; Table 3 . Efficacy outcomes 
